Kala Pharmaceuticals Inc
NASDAQ:KALA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Equity Bancshares Inc
NYSE:EQBK
|
US |
|
A
|
Auckland Real Estate Trust
ASX:AKL
|
AU |
|
CBRE Group Inc
NYSE:CBRE
|
US |
|
H
|
Helio SA
WSE:HEL
|
PL |
|
M
|
Magnit PAO
LSE:MGNT
|
RU |
|
D
|
Douglas AG
XETRA:DOU
|
DE |
|
S
|
S-Pool Inc
TSE:2471
|
JP |
|
Intelligent Wave Inc
TSE:4847
|
JP |
|
Eregli Demir ve Celik Fabrikalari TAS
IST:EREGL.E
|
TR |
|
Z
|
Zall Smart Commerce Group Ltd
HKEX:2098
|
CN |
Kala Pharmaceuticals Inc
Research & Development
Kala Pharmaceuticals Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kala Pharmaceuticals Inc
NASDAQ:KALA
|
Research & Development
-$23.7m
|
CAGR 3-Years
18%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Research & Development
-$14.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Research & Development
-$9.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-5%
|
|
|
Pfizer Inc
NYSE:PFE
|
Research & Development
-$10.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Research & Development
-$15.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Research & Development
-$13.3B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
Kala Pharmaceuticals Inc
Glance View
Kala Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Arlington, Massachusetts and currently employs 192 full-time employees. The company went IPO on 2017-07-20. The firm's product candidate includes EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% and INVELTYS (loteprednol etabonate ophthalmic suspension) 1%. Its EYSUVIS product is a short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. INVELTYS product is a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. The firm's AMPPLIFY technology uses selectively-sized nanoparticles that each have a coating. The firm also has a pipeline of development programs, including a clinical-stage secretome product candidate, KPI-012, initially targeting persistent corneal epithelial defects (PCED) and multiple new chemical entity (NCE) preclinical development programs targeted to address unmet medical needs.
See Also
What is Kala Pharmaceuticals Inc's Research & Development?
Research & Development
-23.7m
USD
Based on the financial report for Sep 30, 2025, Kala Pharmaceuticals Inc's Research & Development amounts to -23.7m USD.
What is Kala Pharmaceuticals Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-2%
Over the last year, the Research & Development growth was -10%. The average annual Research & Development growth rates for Kala Pharmaceuticals Inc have been 18% over the past three years , -2% over the past five years .
